People: Tyratech Inc (TYR.L)

TYR.L on London Stock Exchange

10.50GBp
3:00am EST
Price Change (% chg)

0.00p (+0.00%)
Prev Close
10.50p
Open
10.50p
Day's High
10.50p
Day's Low
10.50p
Volume
0
Avg. Vol
72,971
52-wk High
83.00p
52-wk Low
7.00p

view people for:

Summary

Name Age Since Current Position
Reade, Alan 58 2010 Executive Chairman of the Board
Bigsby, Keith Chief Financial Officer, Group Secretary, Executive Director
Vernon, Geoffrey 56 2010 Non-Executive Director
Riley, Barrington 2007 Non-Executive Director
Regan, Patrick 2009 Non-Executive Director
Noonan, Kenneth 61 Senior Independent Non-Executive Director
» Insider Trading

Biographies

Name Description
Reade, Alan Mr. Alan John Reade has been appointed as Executive Chairman of the Board of Tyratech Inc. He is owner of Global Strategy Expression Limited, a consulting and advisory services business in the life sciences industry. From 2000 until his retirement in 2005, he served as executive chairman of Merial Limited, a animal health company and joint venture between Merck & Co. Inc. and Sanofi-Aventis. Earlier in his career he was head of global integration at Aventis, where he was in charge of merger integration, and Chief Executive Officer and member of the Global Executive Committee at Rhone-Poulenc Inc. He previously has been a director of Sygen International and IFAHah, a global animal health association as well as more than 40 Merial subsidiaries. He is chairman of the Remuneration Committee and member of the Nominations Committee.
Bigsby, Keith Mr. Keith Edward Bigsby is Chief Financial Officer, Group Secretary, Executive Director of Tyratech Inc. He was appointed on April 27, 2007. After qualifying as a Accountant, Mr. Bigsby has had over 30 years of senior financial management and board room experience in the technology sector. He has held senior finance positions across Europe, the USA and the Far East, a significant proportion of which has been as Chief Financial Officer (including for publicly listed companies) most recently at Geotrupes Energy Plc and Tdpole Technology Plc. Prior to this he was for six years the European Regional CFO for Wang and held Finance Director roles in the and France for Sun Microsystems. He has a significant background in complex business environments, strategic planning and process re-engineering.
Vernon, Geoffrey Mr. Geoffrey Nicholas Vernon is Non-Executive Director of Tyratech Inc. He is Chairman of XLTech Group, Inc. and is a former executive director of Rothschild asset Management Ltd., partner of the venture capital group Aadvent Limited, and has over 20 years’ experience in healthcare and life sciences. Dr. Vernon is chairman and/or non-executive director of a number of quoted and privately owned companies in the UK, Germany, Ireland and Israel. He is also a Fellow of the Institute of Directors and one of the first directors in the UK to be admitted as a Chartered Director. He is member of the Audit Ccommittee and chairman of the Nomination Committee.
Riley, Barrington Mr. Barrington Marshall Riley is Non-Executive Director of Tyratech Inc. He was appointed on May 25, 2007. After qualifying as a Chartered Accountant, he joined the Bowater Organisation, where he had responsibility for the finance function at several operations. from there he moved to FMC Corporation, the U.S. conglomerate where he had finance and general management responsibilities for a specialty chemical operation, and also oversaw the head office finance function for all UK operations. he joined Proteus international plc in 1995 as finance Director and was closely involved in the merger with therapeutic Antibodies inc. in 1999, which became Protherics Plc where he was finance Director until 2007. He is chairman of the Audit Committee and member of the nominations Committee.
Regan, Patrick Mr. Patrick Regan has been appointed as a Non-Executive Director of TyraTech, Inc. with effect from 16 September 2009. Mr Regan thirty seven joins the Board as a representative of the Laurus-Valens Group, the parent Group of PetroTech Holdings Corporation. He brings to the Board over sixteen years of financial analysis, corporate management, investment banking and venture capital experience gained in the US. Mr. Regan has been a senior managing director for Laurus Capital Management LLC since 2001 and has also served the same role at Valens Capital Management LLC since its establishment in 2007. In addition to his fund management experience at Laurus-Valens, he has spent four years as a financial analyst at Geller & Company, a financial services accounting firm, primarily providing CFO functions to private companies and financial planning for high net worth individuals. At Geller, he was involved in private placement financing, management consulting and general corporate finance functions. Between 1999 and 2001, Mr. Regan was an associate at Tower Hill Capital Group, an investment banking boutique and venture capital firm. Mr. Regan has a Bachelor of Science in Business and Economics from Lehigh University and an Masters of Business Administration from Fordham University. Mr. Regan has no other previous or current Directorships.
Noonan, Kenneth Dr. Kenneth Daniel Noonan is Senior Independent Non-Executive Director of Tyratech Inc. He is a Partner at Lek Consulting LLP based in London, where he leads the firm’s European life sciences practice, with responsibility for pharmaceuticals, biopharmaceuticals, medical device and diagnostic as well as research product sectors. He is currently a technology partner at Advanced Technology Ventures, a US based venture capital fund. Other positions held by Dr. Noonan included Senior Vice President of Corporate Development for Applera Corporation Vice President at Booz-Allen & Hamilton and head of its European Pharmaceutical Practice. He currently serves on the Board of Orchid Biosciences, Inc. and Intercept Pharmaceuticals, Inc. Dr Noonan holds a B.S from St. Josephs University and a Ph.D. in Biochemistry from Princeton University. He is a member of the Audit Committee and of the Remuneration Committee.

Basic Compensation

Name Fiscal Year Total
Reade, Alan --
Bigsby, Keith 265,000
Vernon, Geoffrey 84,734
Riley, Barrington --
Regan, Patrick --
Noonan, Kenneth --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Reade, Alan 0 0
Bigsby, Keith 0 0
Vernon, Geoffrey 0 0
Riley, Barrington 0 0
Regan, Patrick 0 0
Noonan, Kenneth 0 0

Insider Trading

» Full list on Insider Trading
view people for: